Sunday, November 13, 2016

BRIEF-Alnylam Pharmaceuticals, Medicines Co announce publication of Phase 1 Clinical Data with Inclisiran

* Results from study showed doses 300 mg significantly

reduced pcsk9 and ldl cholesterol for at least 6 months

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)